Program at a Glance

Please Note: All session times for ICKSH 2022 are in Korea Standard Time (KST) UTC +9.
Room Room 1 Room 2 Room 3 Room 4
Date Friday, April 1, 2022
08:00-09:00 Registration
9:00-10:30 [JS03] ASH-KSH Joint Symposium
- Histiocytosis
[SS07] Stem Cell Biology [SS08] Thrombosis & Hemostasis  [ES04] Plasma Cell Disorder
Biologic and clinical consequences of the BRAFV600E mutation in langerhans cell histiocytosis
Kenneth McClain, USA
Losing sense of self and surroundings: hematopoietic stem cell aging and leukemic transformation
Emmanuelle Passegue, USA
Mechanism of thrombosis and bleeding in viral infection: focusing on COVID19
Marcel Levi, UK
Diagnosis and management of monoclonal gammopathy of clinical significance
Hyungwoo Cho, Korea
Advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis
Kim E. Nichols, USA
Hematopoietic stem and progenitor cell signaling in the niche
Peter Kurre, USA
COVID-19 vaccine related hematologic manifestations
Soo-Mee Bang, Korea
Update in the POEMS syndrome
Yu Ri Kim, Korea
Current status of diagnosis and treatment of Langerhans cell histiocytosis in Korea
Kyung-Nam Koh, Korea
Thrombopoietin as an expansion factor for hematopoietic stem cells
Toshio Suda, Japan
Thrombotic thrombocytopenic purpura in 2022: novel therapies and focus on
long term outcomes
Shruti Chaturvedi, USA
Update in the primary plasma cell leukemia
Sung-Hoon Jung, Korea
Adult hemophagocytic lymphohistiocytosis in Korea
Seok Jin Kim, Korea
10:30-11:15 Plenary Lecture  II 
Rational development of targeted therapies to cure molecular subtypes of DLBCL
Louis M. Staudt, USA
11:15-11:30 Break
11:30-12:10 [SY05] Kyowa Kirin [SY06] Otsuka [SY07] Roche [SY08] BMS-celgene
Role of romiplostim in ITP and AA
Jun Ho Jang, Korea
The updated information of ponatinib use in chronic myeloid leukemia
Jorge E. Cortes, USA
Strategic treatment for diffuse large B-Cell lymphoma; incorporating polatuzumab to DLBCL
Christopher Flowers, USA
Optimal treatment with IMiDs in newly diagnosed multiple myeloma
Luciano J. Costa, USA
12:10-12:40 E-poster Exhibition
12:40-13:40 [OP04] ALL [OP05] Anemia, BMF, CML, MPN [OP06] MM [OP07] Platelet, Transfusion
13:40-13:55 Break
13:55-14:40 Presidential Symposium
Toward precision medicine in AML
Hartmut Döhner, Germany
14:40-16:10 [MS01] MOU Country Session - MM
[SS09] MDS [SS10] ALL [ES05] AA and BMF
Managing multiple myeloma in a resource-limited region: diagnosis and treatment
in Armenia
Yervand K. Hakobyan, Armenia
Pathophysiology of spliceosome mutations
in MDS
Andrea Pellagatti, UK
Chemotherapy vs. allogeneic HSCT for Ph–negative adult ALL
Josep-Maria Ribera, Spain
Genetics and genomics of bone marrow failure syndrome
Hyun-Young Kim, Korea
Renal involvement in plasma cell disorder: learning from real-life practice
Suporn Chun, Thailand
Role of extracellular vesicles and miRNA in MDS
Sophie Park, France
Clonal heterogeneity in ALL
Jan Cools, Belgium
Aplastic anemia: transplant vs non-transplant options
Ik-Chan Song, Korea
Treatment sequence decision in multiple myeloma considering reimbursement status
Youngil Koh, Korea
Challenges in the diagnosis and treatment of overlap MDS/MPN syndromes
Antonio Almeida, Portugal
Adoptive cellular immunotherapies based on chimeric antigen receptors
Pablo Menendez, Spain
Overview of bone marrow failure syndrome
Meerim Park, Korea
16:10-16:25  Break
16:25-17:55 [JS04] EHA-KSH Joint Symposium
[SS11] Advanced Technology [SS12] Benign Hematology (Anemia) [ES06] Lymphoma
Failing a second-generation TKI: when the guidelines don’t always help
Jane Apperley, UK
Hematopoiesis and leukemia through the lens of single cell genomics
Lars Velten, Spain
The iron-erythropoiesis cross-talk in health and disease
Antonella Nai, Italy
Lymphoma pathology: basic immunohistochemistry for lymphoma diagnosis
Junhun Cho, Korea
Discontinuation of tyrosine kinase inhibitors in CML patients in clinical practice
Antonio Almeida, Portugal
Computer vision in hematologic malignancies
Oscar Brück, Finland
Autoimmune hemolytic anemia: state-of-the-art hypotheses on pathogenesis and their application to treatment
Bruno Fattizzo, Italy
Staging and response assessment of lymphoma
Kwai Han Yoo, Korea
Second and later line therapy: the role of ponatinib in Korean patients with CML
Jeong-Ok Lee, Korea
Hydrogel-based stamping technology for solution-free blood cell staining
Dongyoung Lee, Korea
Cold agglutinin disease: an update on pathogenesis and future prospects on therapy
Sigbjørn Berentsen, Norway
Treatment of indolent lymphoma
Seong Hyun Jeong, Korea
Stopping tyrosine kinase inhibitor in CML; perspectives from Korean data
Hawk Kim, Korea
Organized by
Supported by

Sponsored by